Biomea Fusion Announces Topline Results from Phase II COVALENT-111 Trial of Icovamenib in Type 2 Diabetes
核心洞察
Biomea Fusion will host a conference call on December 17, 2024, to present topline results from the Phase II COVALENT-111 trial of icovamenib in type 2 diabetes (搜索).
The COVALENT-111 trial evaluates the safety and efficacy of icovamenib, an oral covalent small molecule, in patients with type 2 diabetes (搜索).
Biomea Fusion focuses on developing covalent small molecules for diabetes (搜索), obesity (搜索), and genetically defined cancers, utilizing its proprietary FUSION™ System.
Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, will host a conference call and webcast on Tuesday, December 17, 2024, at 8:00 am EST to present topline results from its Phase II COVALENT-111 trial of icovamenib in patients with type 2 diabetes (搜索) (T2D). The company is dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes (搜索), obesity (搜索), and genetically defined cancers.
The COVALENT-111 trial is a Phase II study evaluating the safety and efficacy of icovamenib, an investigational oral covalent small molecule, in adults with T2D. The primary endpoint is focused on assessing glycemic control and safety over a specified treatment period.
Biomea Fusion is leveraging its proprietary FUSION™ System to discover, design, and develop a pipeline of next-generation covalent-binding small-molecule medicines. These medicines are designed to maximize clinical benefit for patients, with the goal of significantly impacting disease treatment and potentially achieving cures.
Interested parties can access the live webcast of the investor update via the Investors and Media section of Biomea Fusion’s website. A replay of the presentation will be archived on the company’s website following the event.
Biomea Fusion is committed to addressing unmet medical needs in diabetes (搜索), obesity (搜索), and genetically defined cancers through the development of innovative covalent small molecule therapies. Their research focuses on creating drugs with greater target selectivity, lower drug exposure, and the potential for deeper, more durable responses compared to conventional non-covalent drugs.